Yes, the analysts estimate was a loss of $.23. revenue was 58.9M vs analysts estimate of 43.78M.
Enzon has a negative retained earnings of $79.3 M on its balance sheet. So if Enzon is sold, can the buyer use this negative earning to reduce its taxes or this negative figure on the balance sheet would be worthless to a buyer?
FDA says it warned the company repeatedly about the need for having a placebo group. The company denies it. I suspect new lawsuits will be initiated because the company did not reveal such info to shareholders. I guess that must also have been the reason there was bad blood between the FDA and the former company CEO, Chris Garabedian, because he probably was saying the company was not going to follow FDA's recommendation to include the placebo group.
The question is in a jury trial whom the jury would believe. If I were on the jury I would probably believe government agents rather company CEO's. I simply would not see why government employees lie as opposed to a company executive.
"Persistence: Of the patients who have started on treatment, approximately 15% discontinued treatment within the first three months of initiation."
I expected much higher discontinuation than 15%. so I consider the above to be very positive even though the revenue and earnings came below analysts estimates.
Very good coverage of the pipeline. That is certainly a positive as opposed to previous reports.
Even though the expected revenue guidance was a little below previous guidance, I think it is still a very respectable sum which will hopefully makes us profitable for 2016.
for revenue is 439.36M. Last quarter we had revenue of 417.94M
Their earnings estimate is $.29. Last quarter we had earnings of I believe $-.30
Let's hope today's figures will at least meet analysts estimates.
Ofjames, one of thumb ups above was mine. yo funny!
" he's been with his secretary since Sirna"
I do not like HR and believe he should be fired by the BOD for several poor drug trial plans as well as for robbing the shareholders through his stock options that are not well deserved at all BUT NOT FOR WHATEVER RELATIONS HE HAD WITH HIS SECRETARIES. If a person fall in love with his secretary and marries her I do not see any thing wrong with that, SO GET OVER HR MARRYING HIS SECRETARY!!
Now about your above statement, I was just curious about "Since Sirna." Please enlighten me.
Any bounces in biotechs will be temporary as long as Hillary, the baitch, has a chance of becoming president. Her statements about drug price controls many months ago( which BTW is what she was proposing when Bill appointed her on a committee to make recommendation way back), have contibuted to biotechs being slammed by investors. We just have to work to defeat that baitch. Unfortunately, the Republican party does not seem to be giving us a good choice for president either.
These are bad times but we have to hold our biotechs because Hillary, if elected, will not be able to accomplish any of her stupid agendas because both houses will not approve her stupid ideas. As a lifelong democrat I plan to vote for Republican senators and reps to make sure Hillary will not get away with her stupid agenda.
"you obviously didn't read or understand the sarcasm in my statement."
Oh thanks for enlightening us as to what you meant. I did not have a clue, oh great one!
Please continue to enlighten us. hehehehe.
So you are saying brain transplant success rates are high also. Man you are very smart. So please enlighten us with some more of your wisdom.
"Best and much cheaper is a double lung transplant."
Yes, like there are lots of lungs are waiting in line to be transplanted!!! Get real pal.
Vertex sinks after CF drug penetration seen falling short of expectations The shares of Vertex Pharmaceuticals (VRTX) are falling after research firm Stifel predicted that the penetration of the company's Orkambi drug would fall short of expectations. Orkambi is used to treat cystic fibrosis. WHAT'S NEW: After surveying 47 U.S. cystic fibrosis doctors, Stifel analyst Adam Walsh predicted that Orkambi's share of the U.S. market would reach 70% in a year, down from his initial projection of 90%. The analyst now predicts that peak Orkambi sales will come in at $3.3B, down from his previous projection of $5B. Moreover, Walsh lowered his outlook for the drug's EU gross price, citing pricing for the drug in Germany and the U.K. The analyst cut his price target on Vertex to $108 from $140, but he kept a Buy rating on the shares, citing what he sees as the company's "high growth potential, advancing pipeline and attractive valuation." WHAT'S NOTABLE: On March 23, the U.K.'s National Institute for Health and Care Excellence, or NICE, issued draft guidance which did not recommend Orkambi. NICE said that the drug was much more expensive than existing treatments and only produced slightly better results. However, in a note to investors that day, Piper Jaffray analyst Edward Tenthoff wrote that NICE's decision will not impact Vertex's revenue in 2016, adding that he expects talks between Vertex and NICE on the issue to continue. PRICE ACTION: In morning trading, Vertex fell 2.3% to $77.68. 13 May VRTX Vertex 03/23/16 PIPR 03/23/16 JEFF 02/05/16 LEER 02/05/16 PIPR TODAY'S FREE FLY STORIES WATT 12:46 Energous in talks to license wireless technology to at least six companies » Reuters is reporting that… 17 May 12:45 Breaking General news story » Cleveland Fed President… 12:45 Breaking General news story » Week of 4/1 Baker-Hughes… 12:40 U.S. capacity utilization rates were revised sharply lower » U.S. capacity utilization… GDX 12:39 On The Fly: ETF fund flow highlights » Flows we
Thanks for the info and suggestion. I will take a look. Nevertheless, I believe the management should discuss these development in detail in their quarterly reports as well as in their conference calls and presentations. Many of us do not have a clue what is going on unless the management informs us. Again thanks for your response.